- Authors: Nicola A. Hanania, MD
- CME / ABIM MOC Released: 1/31/2020
- Valid for credit through: 1/31/2021
Target Audience and Goal Statement
This activity is intended for pulmonologists, allergists & clinical immunologists, and primary care physicians.
The goal of this activity is to increase clinicians’ competence in identifying patients with allergic phenotypes and selection of biologic therapies for the treatment of severe asthma.
Upon completion of this activity, participants will:
- Have greater competence related to
- Identifying severe asthma phenotypes
- Selection of appropriate biologic therapy in severe asthma based on phenotypic profile
- Nicola A. Hanania, MD Associate Professor of Pulmonary Medicine
Director Airways Clinical Research Center Baylor College of Medicine
- Disclosure: Nicola A. Hanania, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GlaxoSmithKline; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Theravance, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Novartis Pharmaceuticals Corporation; Sanofi Genzyme
- Karen Badal, MD, MPHSenior Medical Education Director, Medscape, LLC
- Disclosure: Karen Badal, MD, MPH, has disclosed the following relevant financial relationships:
Owns stock, stock options, or bonds from: Kallyope Inc.
- Kimberly Storck, PharmD, RPhSenior Medical Writer, Medscape, LLC
- Disclosure: Kimberly Storck, PharmD, RPh, has disclosed no relevant financial relationships.
Developed through a partnership between Medscape and CHEST.
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
- Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity. Contact This Provider
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact CME@medscape.net